GlassScriptPhysician profile
Walter C Vogel
NPI 1629087085
$7,619.63
in general payments reported to CMS, 2019-2025
61 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $710 · 2021: $1,267 · 2022: $1,689 · 2023: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $620.46 | 2019-2023 | Imfinzi, Calquence, Enhertu |
| Janssen Biotech, INC. | $555.08 | 2019-2023 | Darzalex, Tecvayli, Erleada |
| Genentech USA, INC. | $512.80 | 2019-2023 | Tecentriq, Venclexta, Phesgo |
| Bayer Healthcare Pharmaceuticals INC. | $489.33 | 2019-2023 | |
| Amgen INC. | $352.58 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Merck Sharp & Dohme LLC | $316.26 | 2019-2023 | Keytruda, Lynparza |
| Celgene Corporation | $310.75 | 2019-2023 | Pomalyst |
| Incyte Corporation | $291.74 | 2019-2023 | Monjuvi, Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $271.07 | 2019-2023 | Opdivo |
| Genzyme Corporation | $250.36 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $215.49 | 2019-2023 | |
| Pfizer INC. | $212.01 | 2019-2023 | |
| Gilead Sciences, INC. | $206.95 | 2021-2023 | Trodelvy |
| Daiichi Sankyo INC. | $182.26 | 2019-2023 | Enhertu, Injectafer |
| Seagen INC. | $174.54 | 2019-2023 | Padcev, Adcetris, Tukysa |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.